The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BNTC | +51.14% | -66.49% | -19.62% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +247% |
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.12M | -29.7% |
| Market Cap | $307.13M | 1512.5% |
| Market Cap / Employee | $16.16M | 0.0% |
| Employees | 19 | 18.8% |
| Net Income | -$8.81M | -86.5% |
| EBITDA | -$9.72M | -78.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $97.86M | 92.1% |
| Accounts Receivable | $0.03M | -85.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.50M | 0.0% |
| Short Term Debt | $0.35M | 24.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -40.28% | 36.5% |
| Return On Invested Capital | -949.77% | -12.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.53M | -153.6% |
| Operating Free Cash Flow | -$8.53M | -153.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.96 | 3.52 | 4.02 | 3.06 | 84.97% |
| Price to Sales | 136.42 | 1962.22 | - | ||
| Price to Tangible Book Value | 1.96 | 3.52 | 4.02 | 3.06 | 84.97% |
| Enterprise Value to EBITDA | -5.29 | -23.52 | -39.62 | -39.58 | 987.77% |
| Return on Equity | -48.2% | -46.9% | -48.6% | -42.3% | -53.85% |
| Total Debt | $0.21M | $0.14M | $0.96M | $0.85M | 198.94% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
